COVID Antibodies and Immunity
No me gusta!
The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.
Dr. Mizuho Morrison & Dr.Jenny Beck Esmay both having had covid themselves, briefly discuss the clinical course and what presence of IgM vs. IgG signifies. They discuss what we currently know about antibody testing (national availability, reliability, sensitivity) as well as convalescent plasma transfusion (CPT) and criteria for donation vs. recipient.
published on 6/1/20
References:
-
Rajendran K et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020 May https://www.ncbi.nlm.nih.gov/pubmed/32356910
-
Shen C et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27. doi: 10.1001/jama.2020.4783
-
Luke T et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006 Oct 17; 145(8): 599–609.
-
Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial Agents and Chemotherapy Aug 1994, 38 (8) 1695-1702.
-
Jenkins J et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. J Infect Dis. 2015 Jan 1; 211(1): 80–90.
-
Hung I et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013 Aug; 144(2): 464–473.
Additional references: